3Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 Diabetes: the insulin resistance atheroselerosis stuely[J].Diabetes, 2004, 53: 2623-2632.
4Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome[J].J Clin Endocrinol Metab, 2007, 92: 3490-3497.
5Neuschwander Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome[J].Am J Med Sci, 2005, 330: 326-335.
6Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes[J].J Biol Chem, 1990, 265: 8854-8862.
7Adiels M, Westerbacka J, Soro-Paavonen A, et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance[J]. Diabetologia, 2007, 50: 2356-2365.
8Adiels M, Olofsson SO, Taskinen MR, et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome[J]. Arterioscler Thromb Vasc Biol, 2008, 28: 1225-1236.
9Diehl AM. Nonalcoholic fatty disease abnormalities in macrophage function and cytokines[J].Am J Physiol, 2002, 282: 1-5.
10Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochoadrial superoxide production blocks three pathways of hyperglycaemic damage[J]. Nature, 2000, 404: 787-790.
8Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
9Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
10Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
